AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

August 11, 2017: By Jon Swedien

AGTCApplied Genetic Technologies Corporation announced Aug. 10 that it has filed an investigational new drug application (IND) with the US FDA to conduct a Phase I/II clinical trial for the company’s gene therapy candidate for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

AGTC said it plans to start the study in the US in the coming months.

AGTC is currently scheduling patients for enrollment in clinical trials for X-linked retinoschisis (XLRS), as well as for achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, the Alachua, Florida, company said.

On Aug. 3, AGTC announced that the FDA granted orphan drug designation to the XLRP gene therapy candidate. The European Commission granted orphan medicinal product designation for the same indication in 2016.

XLRP is an inherited condition that causes progressive vision loss.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022